Longeveron Q2: Cash Runway to Q4, New Directors, XPRIZE Award
LGVN sits 43% above its 52-week low of $0.475 on elevated volume (2.5× avg).
Summary
Longeveron's Q2 results show a $6.1 million net loss and cash runway only into Q4 2026, but the company added three new directors, won a $1 million XPRIZE award, and expects pivotal ELPIS II data in September.
Key Events · Earnings and Guidance · LGVN
-
Q2 Net Loss Widens
Net loss was $6.1 million for Q2 2026, up 22% from $5.0 million a year ago, driven by higher legal and personnel costs.
-
Cash Runway to Q4 2026
Cash and equivalents were $10.1 million as of June 30, 2026, funding operations only into Q4 2026; company plans additional financing.
-
Three New Directors
Longeveron added three independent directors to its board, strengthening governance ahead of pivotal data.
-
XPRIZE Milestone 2 Award
Company selected as Finalist and Milestone 2 Awardee, receiving $1.0 million to fund future clinical trial for Healthspan competition.
Analysis · LGVN · Life Sciences
Longeveron reported Q2 revenue of $0.3 million, flat year-over-year, with a net loss of $6.1 million. Cash stands at $10.1 million, funding operations only into Q4 2026. The company added three independent directors and received a $1 million XPRIZE Milestone 2 Award. Topline data from the ELPIS II Phase 2b trial in HLHS is expected in September 2026, a near-term catalyst that could redefine the company's outlook.
At the time of this filing, LGVN was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $0.48 to $1.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.